Fibrinogen · Tachosil

What is Fibrinogen?

FIB Grifols is a human plasma-derived fibrinogen preparation given by slow intravenous infusion, with dosing based on target plasma fibrinogen level and measured pre-infusion level. It is studied in congenital afibrinogenemia and hypofibrinogenemia. The fibrinogen in the product converts to fibrin during blood clot formation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Tachosil, FIB Grifols

Drug type

Plasma-derived product

Mechanism

Protein replacement

Pathways

fibrin clot formation, coagulation cascade

Therapy area

Hematology

Developer

Corza Medical Gmbh

In trials of

GRFS

FDA status

Approved as Tachosil (April 5, 2010), BLA125351 · FDA label

✅ FDA-approved uses

• Adjunct to hemostasis in cardiovascular and hepatic surgery

From the indications section of the FDA label (version of Oct 8, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Congenital AfibrinogenemiaHypofibrinogenemia

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Tachosil (2025-10-08), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT04636268

Updated Oct 11, 2026.